Fusion Pharmaceuticals Inc. FUSN
We take great care to ensure that the data presented and summarized in this overview for Fusion Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FUSN
Top Purchases
Top Sells
About FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Insider Transactions at FUSN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 04
2024
|
John Valliant Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
318,147
-100.0%
|
-
|
|
Jun 04
2024
|
Steven Gannon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
56,400
-100.0%
|
-
|
|
Jun 04
2024
|
John J Crowley Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,410
-100.0%
|
-
|
|
Jun 04
2024
|
Mohit Rawat President & CBO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,699
-100.0%
|
-
|
|
Jun 04
2024
|
Christopher P Leamon Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,957
-100.0%
|
-
|
|
Jun 04
2024
|
Eric Burak Chief Technology Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
38,490
-100.0%
|
-
|
|
Aug 31
2023
|
Mohit Rawat President & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
12,843
+50.0%
|
-
|
|
Aug 31
2023
|
Christopher P Leamon Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,957
+50.0%
|
-
|
|
Nov 11
2022
|
Chau Quang Khuong Director |
BUY
Grant, award, or other acquisition
|
Direct |
42,093
+50.0%
|
$84,186
$2.38 P/Share
|
|
Aug 11
2022
|
Steven Gannon |
BUY
Open market or private purchase
|
Direct |
44,400
+44.05%
|
$88,800
$2.03 P/Share
|
|
Apr 27
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,511
-1.4%
|
$27,066
$6.03 P/Share
|
|
Apr 26
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,147
-0.66%
|
$12,882
$6.07 P/Share
|
|
Apr 25
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,036
-0.62%
|
$12,216
$6.03 P/Share
|
|
Apr 21
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
922
-0.28%
|
$5,532
$6.01 P/Share
|
|
Apr 20
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
367
-0.11%
|
$2,202
$6.02 P/Share
|
|
Apr 13
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,994
-3.53%
|
$71,964
$6.41 P/Share
|
|
Apr 12
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,255
-5.09%
|
$127,785
$7.1 P/Share
|
|
Apr 11
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,600
-0.72%
|
$18,200
$7.37 P/Share
|
|
Apr 08
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
826
-0.23%
|
$5,782
$7.52 P/Share
|
|
Apr 07
2022
|
John Valliant Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,255
-0.35%
|
$8,785
$7.56 P/Share
|
Last 12 Months Summary
| Sale (or disposition) back to the issuer | 457K shares |
|---|